<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome (AS)</z:e> is a neurogenetic disorder characterized by <z:hpo ids='HP_0010864'>severe mental retardation</z:hpo>, <z:hpo ids='HP_0002167'>speech disorder</z:hpo>, stereotyped <z:mp ids='MP_0005424'>jerky movements</z:mp>, and a peculiar behavioral profile, with a happy disposition and outbursts of laughter </plain></SENT>
<SENT sid="1" pm="."><plain>Most patients with AS present with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> and suggestive electroencephalographic patterns, which may be used as diagnostic criteria </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To study <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> and response to treatment in a series of patients with AS determined by deletion </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Parent and caregiver interview and medical record review </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">Epilepsy</z:e> Center at the University of SÃ£o Paulo </plain></SENT>
<SENT sid="5" pm="."><plain>PATIENTS: Nineteen patients with AS determined by deletion of chromosome 15q11-13 </plain></SENT>
<SENT sid="6" pm="."><plain>MAIN OUTCOME MEASURES: <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">Epilepsy</z:e> severity, <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> evolution, and response to <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drug treatment </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> patients with AS in this group had <z:e sem="disease" ids="C0014548" disease_type="Disease or Syndrome" abbrv="">generalized epilepsy</z:e>, and 10 (53%) also had <z:e sem="disease" ids="C0014547" disease_type="Disease or Syndrome" abbrv="">partial epilepsy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Main <z:hpo ids='HP_0001250'>seizure</z:hpo> types were atypical absences and myoclonic and tonic-clonic <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Mean age at <z:hpo ids='HP_0003674'>onset</z:hpo> was 1 year 1 month </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0852977" disease_type="Disease or Syndrome" abbrv="">Epilepsy aggravated</z:e> by <z:hpo ids='HP_0001945'>fever</z:hpo> occurred in 10 patients (53%) and <z:hpo ids='HP_0002133'>status epilepticus</z:hpo> in 16 (84%) </plain></SENT>
<SENT sid="11" pm="."><plain>Eighteen patients (95%) had previous or current history of daily <z:hpo ids='HP_0001250'>seizures</z:hpo>, of which 14 (64%) had disabling <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Multiple <z:hpo ids='HP_0001250'>seizure</z:hpo> types were observed in 13 patients (53%) </plain></SENT>
<SENT sid="13" pm="."><plain>History of refractory <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> was reported in 16 patients (84%) </plain></SENT>
<SENT sid="14" pm="."><plain>Parents reported improvement, characterized by decrease in <z:hpo ids='HP_0001250'>seizure</z:hpo> frequency or <z:hpo ids='HP_0001250'>seizure</z:hpo> control, at the mean age of 5.3 years </plain></SENT>
<SENT sid="15" pm="."><plain>Therefore, most of these patients had a period of refractory <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e>; however, improvement occurred during late childhood and puberty </plain></SENT>
<SENT sid="16" pm="."><plain>The best therapeutic response was obtained with <z:chebi fb="0" ids="39867">valproic acid</z:chebi> alone or in association with <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> or clonazepam </plain></SENT>
<SENT sid="17" pm="."><plain><z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">Epilepsy</z:e> was aggravated by carbamazepine, oxcarbazepine, and vigabatrin </plain></SENT>
<SENT sid="18" pm="."><plain>CONCLUSIONS: Patients with AS with deletion have <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> with early <z:hpo ids='HP_0003674'>onset</z:hpo> and stereotyped electroclinical profile regarding <z:hpo ids='HP_0001250'>seizure</z:hpo> type, severity, and response to <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drug treatment </plain></SENT>
<SENT sid="19" pm="."><plain>Another feature of AS is the age-related improvement, even in refractory cases, during late childhood and puberty </plain></SENT>
<SENT sid="20" pm="."><plain>These characteristics are not specific to this syndrome but, when inserted in the proper clinical context, may anticipate diagnosis </plain></SENT>
<SENT sid="21" pm="."><plain>We believe that AS should be considered a differential diagnosis in developmentally delayed infants with severe, generalized, <z:e sem="disease" ids="C0086237" disease_type="Disease or Syndrome" abbrv="">cryptogenic epilepsy</z:e>; however, a proper electroclinical delineation of each genetic group is mandatory </plain></SENT>
</text></document>